Skip to main content

Umbilical cord MSC therapy in Istanbul, from Wharton's jelly

The cells our clinic works with, why this source was chosen, what is checked before a dose reaches you, and how our medical team builds the treatment around your case.

Near-still macro film of a shallow glass dish on a clinic counter holding a pale ribbon of cord tissue in clear fluid. Treatment in Istanbul

Umbilical Cord MSC Therapy at Our Istanbul Clinic

This page explains what umbilical cord msc therapy is, how our medical team plans it, and what treatment in Istanbul involves. It is general information rather than a treatment plan: suitability is confirmed only after our team has reviewed your diagnosis, your records, the alternatives open to you, and the goals you want treatment to support.

At a glance

Umbilical Cord MSC Therapy at a glance

Biological material
Mesenchymal stromal cells isolated from donated umbilical cord tissue after delivery.
How it is given
Depends on your plan. Donor consent, screening, traceability, processing, storage and release testing apply whichever route is used.
Where it sits today
Many uses in autoimmune, neurological and degenerative conditions remain investigational, and we say so when that applies to your case.
Who it may suit
That is decided case by case. This page explains the treatment; suitability is confirmed only after our medical team has reviewed your records.

From cord donation to the dose you receive

Umbilical cord tissue is a well-studied source of mesenchymal stromal cells. The visual follows the material from donation and screening through culture and testing to the dose given in clinic.

Editorial quality pathway showing umbilical cord donation, cell isolation, expansion, laboratory testing, and clinical documentation

Clinical context

Microscopic editorial illustration of mesenchymal stromal cells, culture documentation, and release-testing context

Microscopic research viewIllustrative detail

An illustration of the chain behind an umbilical cord MSC preparation, from donation and donor screening through isolation, expansion, and release testing. The view then moves in to the cells in culture and the release testing behind a dose. Both frames are illustrations of the biology, not footage of a patient or a laboratory result, and this visual does not depict a treatment outcome.
Donation and screening
Consent, maternal and donor history, infectious-disease screening, collection, and chain of custody open the record.
Processing and release
Isolation, expansion, identity markers, sterility, viability, and dose are all checked against defined criteria before release.
Traceable to you
The batch, transport, storage, preparation, and administration stay linked to your file, along with the plan if a reaction occurs.

What Is Umbilical Cord MSC Therapy?

This treatment uses mesenchymal stromal cells from Wharton's jelly, the gelatinous connective tissue inside the umbilical cord that cushions its blood vessels. The cord is donated after a healthy birth, the mother consents in writing, and she is screened for infectious disease before anything is used. It is tissue that would otherwise be discarded, nothing is done to mother or baby to obtain it, and none of the ethical questions attached to embryonic sources arise. Patients searching for umbilical cord stem cells, for UC-MSC therapy or for Wharton's jelly stem cells are looking at this same material.

Our clinic works with this source deliberately, and the reasons are worth knowing. Wharton's jelly is a young perinatal tissue rather than an adult one, unlike cells taken from bone marrow or fat. The cells expand readily in culture, so a whole batch can be grown, characterised and release-tested before any of it reaches a patient. They carry a low-immunogenicity profile, which is why this source is studied for use between unrelated people rather than requiring cells harvested from you. And they have a strong secretory profile: these cells are studied for the signalling molecules they release, which is the mechanism most mesenchymal stromal cell research now centres on.

Every batch arrives with its own record: donor consent and screening, the manufacturing facility and its GMP-aligned processes, identity testing, sterility and endotoxin results, viable cell count, storage conditions and the transport record, gathered into a certificate of analysis. Our team goes through that certificate with you, a physician administers the dose, and the route follows the goal your plan sets rather than habit. Send your medical records for a case review and we will tell you whether this treatment fits your diagnosis and what the plan would contain.

How Umbilical Cord MSC Therapy Works

These are the biological ideas umbilical cord msc therapy is built on. How much of it applies to you depends on your diagnosis, the goals set during your case review, the route of administration and the rest of your clinical picture, which is what our medical team works through with you.

  • These cells work by releasing biological signals that influence the cells around them, a process called paracrine signalling, rather than by travelling to an area of damage and becoming replacement tissue - which is not what the research describes
  • They release cytokines, the proteins cells use to speak to the immune system, and this is where research into an overactive inflammatory response is concentrated
  • Shifting how the immune system behaves rather than suppressing it is called immunomodulation, and it is the most studied property of these cells
  • Growth factors they release are studied for the support they may give to the repair processes tissue already runs for itself
  • Signals that encourage new small blood vessels, called angiogenic signalling, matter because blood supply shapes how tissue recovers
  • Viability, cell count, passage number, storage and dose all shape what actually reaches you, which is why the batch record is part of your treatment plan

Stem cells and exosomes are different.

One is a living cell. The other is a cell-derived messenger. The difference shapes how each is sourced, how it is given, and which one our medical team may propose for your case.

Illustration of a mesenchymal stromal cell releasing extracellular vesicles toward neighboring tissue cells
  1. 01 / SOURCE

    Living source cells

    Mesenchymal stromal cells are living cells. Their behavior depends on source, handling, dose, and biological context.

  2. 02 / SIGNAL

    Released signals

    Cells release soluble factors and extracellular vesicles. Exosomes are one subset of these small vesicles.

  3. 03 / RESPONSE

    Local cell response

    Nearby cells may respond to those signals. That biological rationale is where treatment planning starts, not a promise of a result.

Illustrative visualization, not to scale. It does not predict a treatment response.Stem cells and exosomes explained

Sourcing and handling

Wharton’s jelly: where our cells come from, and why.

We work with mesenchymal stromal cells from Wharton’s jelly, the gelatinous tissue inside the umbilical cord. It is collected after a healthy birth, with written maternal consent, from tissue that would otherwise be discarded. No harm comes to mother or baby, and none of the ethical questions attached to embryonic sources apply here.

It is also a young, perinatal source rather than adult bone marrow or fat, and it has a low-immunogenicity profile — which is why these cells are studied for use between unrelated people rather than requiring a patient’s own. They expand readily in culture, so a batch can be fully characterised and release-tested before any of it reaches a patient, and they are studied above all for what they secrete: the signalling molecules at the centre of most current MSC research. Before treatment begins, our team takes you through the origin of the material in your plan, how it was handled and what was checked.

Illustrated pathway from donated Wharton's jelly umbilical cord tissue through laboratory review to clinical handling
  1. 01 / ORIGIN

    Donation and consent

    The cord is donated after a healthy birth, with written maternal consent and documented donor screening.

  2. 02 / ISOLATION

    Controlled processing

    The cells are isolated from the tissue and expanded in culture, and our team explains where that work is done.

  3. 03 / VERIFICATION

    Release testing

    Identity, sterility, viability and contamination checks are recorded, and the results follow the batch.

  4. 04 / CUSTODY

    Clinical handling

    Storage, transport, preparation and traceability are documented for the material used in your plan.

Illustrative sequence. Materials, tests, and workflows vary by laboratory and protocol.Read the safety guide

Your case review

How Our Medical Team Assesses Suitability

The purpose of the review is clarity. Your diagnosis, medical history, reports, imaging, current medication and the goals that matter to you give our team the context to plan treatment, or to tell you that this route is not right for your case.

  • Autoimmune and inflammatory conditions that are under specialist care and documented in recent reports
  • Neurological diagnoses where a therapeutic goal can be described clearly enough to be reviewed later
  • Joint, tendon and soft-tissue conditions supported by recent imaging
  • Patients who would rather receive a characterised donor batch than undergo a procedure to harvest their own cells
  • Suitability is confirmed after our team assesses active infection, cancer history, pregnancy, immune status, anticoagulation and current medication

Setting Realistic Goals for Your Treatment

Before treatment we agree on what we are aiming for: measures that fit your condition, a realistic period over which to review them, and what would count as no meaningful change. Goals are not predictions. Responses vary between patients and no clinical outcome can be guaranteed.

  • The goal is written into the plan before treatment, in the terms that matter to you, and is reviewed against the baseline we record beforehand
  • Laboratory findings about signalling explain why these cells are studied; they are not a forecast of how one patient will respond
  • Condition-specific follow-up continues alongside your established care and any rehabilitation already in place
  • Repeat treatment is considered only where the review supports it, not scheduled in advance
  • Regenerative medicine is planned individually: responses vary between patients, no clinical outcome can be guaranteed, suitability is confirmed only after medical review, and treatment is planned alongside your existing care

Your next step

Find out whether umbilical cord msc therapy may suit your case

If umbilical cord msc therapy looks relevant to your diagnosis, the next step is a review of your own records by our medical team. If it does not, we can explain which of the other routes we plan may fit better.

Suitability is confirmed only after our medical team has reviewed your records, and treatment is planned alongside the care you already receive.

From Your Records to an Agreed Treatment Plan

How our team moves from your first records review to a plan you can act on: evidence, risk, practical detail and follow-up, settled before you travel.

Send your medical records

Recent reports, imaging, your current medication, and what you hope treatment will help with. It lets our medical team make the review specific to you.

Start your case review
  1. Send your medical records

    Our patient coordination team starts with your confirmed diagnosis, recent reports and imaging, current medications, previous procedures, and the outcomes that matter most to you.

  2. Medical case review

    Our medical team reads the file and decides whether this pathway is relevant to your case, which route would suit it, and where your existing care should stay in the lead.

  3. Read your written treatment plan

    You receive the biological material proposed and its documentation, the preparation and dose, the route, the schedule, the monitoring, the risks, the alternatives, and an itemized cost, in writing.

  4. Plan your treatment in Istanbul

    We confirm appointment timing, how long to stay, airport transfers, accommodation, mobility needs, medication instructions and your local contact before you book travel.

  5. Stay in contact after you go home

    Before treatment we agree what will be measured, when it will be reviewed, who answers your questions once you are home, and how your own clinician is kept informed.

Umbilical Cord MSC Therapy - Frequently Asked Questions

What is Wharton's jelly?

The gelatinous connective tissue inside the umbilical cord, the soft material that surrounds and cushions the cord's blood vessels. It is an unusually rich source of mesenchymal stromal cells, and those cells are what our laboratory isolates and grows. Wharton's jelly is simply the precise name for the material often described more loosely as umbilical cord tissue.

Why Wharton's jelly rather than my own cells?

It is a young perinatal tissue rather than an adult one, it is collected without any procedure on you, and the cells expand readily in culture, so a batch can be characterised and release-tested before a dose is ever prepared. Their low-immunogenicity profile is the reason this source is studied for use between unrelated people. Our medical team explains why it suits your plan.

Are Wharton's jelly stem cells the same as embryonic stem cells?

No, and the two are not related. These are mesenchymal stromal cells taken from the cord after a healthy birth has already happened, with written maternal consent, from tissue that would otherwise be discarded. None of the ethical questions attached to embryonic sources arise here, and the donation is documented for every batch.

What else is this treatment called?

Umbilical cord stem cells, UC-MSC therapy, and Wharton jelly MSC treatment written without the apostrophe are all names for the same material. What actually differs between one plan and another is the preparation, the dose and the route, which is what your written plan sets out.

Do I need to be a tissue match?

Routine tissue matching is not generally used for donor-derived MSC products, and the low-immunogenicity profile of this cell type is a large part of why. That does not make the cells invisible to your immune system, so the treating physician reviews compatibility, infusion and immune considerations for your case.

Where does the tissue come from, and is the donation ethical?

From mothers who consent in writing to donate the cord after a healthy birth, following eligibility and infectious-disease screening. No harm comes to mother or baby, the cord would otherwise be discarded, and chain of custody and de-identification are documented. You can ask to see that part of the record along with the certificate of analysis.

What quality documentation do I receive?

The batch certificate of analysis: identity testing, sterility and endotoxin results, viable cell count, passage, storage conditions and release criteria, alongside the donor screening and traceability record. Our team goes through it with you before the dose is given.

Are there side effects?

Possible effects depend on the route and the individual, and include infusion or injection reactions, temporary fever or fatigue, and procedure-related risks such as infection at the site. Your plan lists what applies to you, what we monitor for, and who to contact if something concerns you afterwards.

How do I find out whether I may be suitable for treatment in Istanbul?

Send your confirmed diagnosis, recent reports and imaging, current medications and medical history to our patient coordination team. Our medical team reviews suitability case by case and tells you in writing whether this pathway fits your situation, and what it would involve.

How long do international patients stay in Istanbul?

It depends on the plan our medical team proposes: the procedure, the route, the monitoring, your mobility and the follow-up all affect it. Your written schedule states the number of days before you book flights or accommodation.

Is this treatment safe?

No medical treatment is free of risk, and we are direct about that. Our team reduces the risks that can be reduced: screened donor material, batch testing before release, administration by a physician in a clinical setting, monitoring during and after the procedure, and a written account of the side effects and contraindications that apply to your plan.

What results can I expect?

Your plan states a therapeutic goal and how it will be measured, not a promised outcome. Our medical team explains what change would be meaningful in your case, when it will be reviewed, and what we would do next if that review shows no benefit.

How much does treatment cost in Istanbul?

Pricing is case-specific: the material, the preparation and dose, the route, the number of sessions, the monitoring and any travel services all affect it. Our patient coordination team sends an itemized written estimate so you can see what each part of the plan costs before you commit.

What does the international patient program include?

Your estimate lists the medical review, tests, the procedure itself, monitoring, medications, airport transfers, accommodation arrangements, written discharge information and follow-up as separate lines, so you can see what is included and what is not.

How this guide is maintained

How This Guide Is Written and Reviewed

Editorial reviewHow this guide is reviewed

This guide carries a last-reviewed date. Review asks whether the way we describe umbilical cord msc therapy and the research behind it still matches the published literature.

Where the evidence is limited, mixed or still emerging, the page says so rather than settling the question in the treatment's favour.

SourcingWhat we count as a source

Peer-reviewed human studies, trial registry entries and regulatory guidance. Laboratory and animal work is labelled as preclinical, and individual case reports are described as case reports.

Marketing material, including our own, is not treated as evidence.

Your treatment planWhat our medical team sets out

Before you agree to anything, our team can set out in writing the material proposed for your plan, how it is sourced, processed and release-tested, the route of administration, the monitoring plan, the full cost with exclusions, and who is clinically responsible for your care.

If any part of that is unclear, ask us. Your plan should make sense to you before you travel.

Wide evening view of the Bosphorus with a ferry, illuminated waterfront, and suspension bridge

Evening on the Bosphorus, with a ferry and the bridge beyond. It shows the city you would travel to, not our clinic, your accommodation, or a service included in a plan.

Cell source documentation comes before travel

Donor screening, tissue source, processing, cell identity, release tests, dose, administration route, and monitoring are documented before your Istanbul visit is arranged.

More from our clinic

Planning your umbilical cord msc therapy in Istanbul

The practical side of treatment at our clinic: what the research shows, who may be suitable, what a plan costs, and how your stay in Istanbul and your follow-up are arranged.

Cost, Outcomes & Istanbul

Medical Disclaimer: This content is educational and is not personal medical advice. Regenerative medicine treatments are planned individually, responses vary and no clinical outcome can be guaranteed. Suitability is confirmed only after medical review, and treatment is planned alongside your existing care.

International patient support

Talk to our medical team about Umbilical Cord MSC Therapy.

Send your diagnosis, reports, imaging and current medication. Our medical team explains which options may fit your case, what the treatment involves, and what your stay in Istanbul would look like.

Your review starts from home

Nothing needs to be booked to begin. Our patient coordination team plans your visit to Istanbul once your treatment plan is agreed.